GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0002064 | Colorectum | AD | epithelial cell development | 89/3918 | 220/18723 | 2.98e-11 | 3.52e-09 | 89 |
GO:0034329 | Colorectum | AD | cell junction assembly | 136/3918 | 420/18723 | 2.02e-08 | 1.15e-06 | 136 |
GO:0070997 | Colorectum | AD | neuron death | 114/3918 | 361/18723 | 1.13e-06 | 3.72e-05 | 114 |
GO:0043087 | Colorectum | AD | regulation of GTPase activity | 110/3918 | 348/18723 | 1.64e-06 | 5.03e-05 | 110 |
GO:0007623 | Colorectum | AD | circadian rhythm | 72/3918 | 210/18723 | 4.50e-06 | 1.21e-04 | 72 |
GO:1990090 | Colorectum | AD | cellular response to nerve growth factor stimulus | 26/3918 | 53/18723 | 4.87e-06 | 1.28e-04 | 26 |
GO:0048511 | Colorectum | AD | rhythmic process | 94/3918 | 298/18723 | 1.00e-05 | 2.34e-04 | 94 |
GO:0007265 | Colorectum | AD | Ras protein signal transduction | 104/3918 | 337/18723 | 1.01e-05 | 2.35e-04 | 104 |
GO:0031667 | Colorectum | AD | response to nutrient levels | 138/3918 | 474/18723 | 1.22e-05 | 2.68e-04 | 138 |
GO:1901214 | Colorectum | AD | regulation of neuron death | 99/3918 | 319/18723 | 1.26e-05 | 2.76e-04 | 99 |
GO:1990089 | Colorectum | AD | response to nerve growth factor | 26/3918 | 56/18723 | 1.71e-05 | 3.59e-04 | 26 |
GO:0051056 | Colorectum | AD | regulation of small GTPase mediated signal transduction | 94/3918 | 302/18723 | 1.81e-05 | 3.76e-04 | 94 |
GO:0046777 | Colorectum | AD | protein autophosphorylation | 74/3918 | 227/18723 | 2.48e-05 | 4.76e-04 | 74 |
GO:0010975 | Colorectum | AD | regulation of neuron projection development | 129/3918 | 445/18723 | 2.88e-05 | 5.37e-04 | 129 |
GO:0007409 | Colorectum | AD | axonogenesis | 122/3918 | 418/18723 | 3.36e-05 | 6.15e-04 | 122 |
GO:0051402 | Colorectum | AD | neuron apoptotic process | 77/3918 | 246/18723 | 8.07e-05 | 1.28e-03 | 77 |
GO:0031346 | Colorectum | AD | positive regulation of cell projection organization | 104/3918 | 353/18723 | 8.26e-05 | 1.30e-03 | 104 |
GO:0061564 | Colorectum | AD | axon development | 132/3918 | 467/18723 | 8.40e-05 | 1.31e-03 | 132 |
GO:1901215 | Colorectum | AD | negative regulation of neuron death | 67/3918 | 208/18723 | 8.81e-05 | 1.35e-03 | 67 |
GO:0033674 | Colorectum | AD | positive regulation of kinase activity | 131/3918 | 467/18723 | 1.28e-04 | 1.85e-03 | 131 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04722 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
hsa05216 | Colorectum | AD | Thyroid cancer | 21/2092 | 37/8465 | 3.05e-05 | 2.76e-04 | 1.76e-04 | 21 |
hsa05230 | Colorectum | AD | Central carbon metabolism in cancer | 33/2092 | 70/8465 | 3.61e-05 | 3.19e-04 | 2.03e-04 | 33 |
hsa047221 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
hsa052161 | Colorectum | AD | Thyroid cancer | 21/2092 | 37/8465 | 3.05e-05 | 2.76e-04 | 1.76e-04 | 21 |
hsa052301 | Colorectum | AD | Central carbon metabolism in cancer | 33/2092 | 70/8465 | 3.61e-05 | 3.19e-04 | 2.03e-04 | 33 |
hsa052302 | Colorectum | SER | Central carbon metabolism in cancer | 25/1580 | 70/8465 | 5.43e-04 | 4.51e-03 | 3.27e-03 | 25 |
hsa047222 | Colorectum | SER | Neurotrophin signaling pathway | 35/1580 | 119/8465 | 2.80e-03 | 2.02e-02 | 1.47e-02 | 35 |
hsa052303 | Colorectum | SER | Central carbon metabolism in cancer | 25/1580 | 70/8465 | 5.43e-04 | 4.51e-03 | 3.27e-03 | 25 |
hsa047223 | Colorectum | SER | Neurotrophin signaling pathway | 35/1580 | 119/8465 | 2.80e-03 | 2.02e-02 | 1.47e-02 | 35 |
hsa052162 | Colorectum | MSS | Thyroid cancer | 21/1875 | 37/8465 | 4.98e-06 | 6.00e-05 | 3.68e-05 | 21 |
hsa047224 | Colorectum | MSS | Neurotrophin signaling pathway | 45/1875 | 119/8465 | 7.04e-05 | 6.55e-04 | 4.02e-04 | 45 |
hsa04210 | Colorectum | MSS | Apoptosis | 44/1875 | 136/8465 | 3.66e-03 | 1.66e-02 | 1.01e-02 | 44 |
hsa052304 | Colorectum | MSS | Central carbon metabolism in cancer | 25/1875 | 70/8465 | 6.50e-03 | 2.64e-02 | 1.62e-02 | 25 |
hsa052163 | Colorectum | MSS | Thyroid cancer | 21/1875 | 37/8465 | 4.98e-06 | 6.00e-05 | 3.68e-05 | 21 |
hsa047225 | Colorectum | MSS | Neurotrophin signaling pathway | 45/1875 | 119/8465 | 7.04e-05 | 6.55e-04 | 4.02e-04 | 45 |
hsa042101 | Colorectum | MSS | Apoptosis | 44/1875 | 136/8465 | 3.66e-03 | 1.66e-02 | 1.01e-02 | 44 |
hsa052305 | Colorectum | MSS | Central carbon metabolism in cancer | 25/1875 | 70/8465 | 6.50e-03 | 2.64e-02 | 1.62e-02 | 25 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NTRK1 | SNV | Missense_Mutation | novel | c.586N>A | p.Leu196Met | p.L196M | P04629 | protein_coding | deleterious(0.01) | possibly_damaging(0.652) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
NTRK1 | SNV | Missense_Mutation | | c.956N>A | p.Gly319Asp | p.G319D | P04629 | protein_coding | tolerated(0.09) | benign(0.236) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NTRK1 | SNV | Missense_Mutation | | c.1112C>T | p.Ser371Phe | p.S371F | P04629 | protein_coding | deleterious(0.02) | benign(0.163) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
NTRK1 | SNV | Missense_Mutation | | c.1876N>A | p.Gln626Lys | p.Q626K | P04629 | protein_coding | deleterious(0.01) | benign(0.038) | TCGA-B6-A0I8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
NTRK1 | SNV | Missense_Mutation | rs770090356 | c.1025N>A | p.Arg342Gln | p.R342Q | P04629 | protein_coding | tolerated(0.6) | benign(0.001) | TCGA-BH-A0EB-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
NTRK1 | SNV | Missense_Mutation | | c.1748G>A | p.Arg583His | p.R583H | P04629 | protein_coding | deleterious(0.01) | possibly_damaging(0.685) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
NTRK1 | SNV | Missense_Mutation | | c.286N>G | p.Leu96Val | p.L96V | P04629 | protein_coding | deleterious(0) | probably_damaging(0.944) | TCGA-EW-A1P7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
NTRK1 | SNV | Missense_Mutation | novel | c.625N>C | p.Asp209His | p.D209H | P04629 | protein_coding | deleterious(0.01) | possibly_damaging(0.802) | TCGA-OL-A66J-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NTRK1 | insertion | Nonsense_Mutation | novel | c.1089_1090insGGTTGAG | p.Ala364GlyfsTer2 | p.A364Gfs*2 | P04629 | protein_coding | | | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
NTRK1 | insertion | Frame_Shift_Ins | novel | c.1091_1092insGCAGA | p.Asn365GlnfsTer107 | p.N365Qfs*107 | P04629 | protein_coding | | | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4914 | NTRK1 | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | inhibitor | 363894214 | SITRAVATINIB | |
4914 | NTRK1 | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | | MIM-D3 | TAVILERMIDE | 23836957 |
4914 | NTRK1 | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | | RXDX 101 | | |
4914 | NTRK1 | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | | Pyrrolidinyl urea derivative 11 | | |
4914 | NTRK1 | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | inhibitor | 310264690 | LAROTRECTINIB | |
4914 | NTRK1 | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | | Imidazo[1,2-b]pyridazine derivative 4 | | |
4914 | NTRK1 | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | | METHOTREXATE | METHOTREXATE | 8509220 |
4914 | NTRK1 | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | | ENTRECTINIB | ENTRECTINIB | |
4914 | NTRK1 | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | | Pyrazolo[1,5-a]pyrimidine derivative 14 | | |
4914 | NTRK1 | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, DRUG RESISTANCE | | Pyrazolo[1,5-a]pyrimidine derivative 27 | | |